• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Kura Oncology Inc.

    5/15/26 11:26:19 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KURA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    KURA ONCOLOGY, INC.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    50127T109

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    50127T109


    1Names of Reporting Persons

    Armistice Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,736,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,736,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,736,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.23 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP Number(s):
    50127T109


    1Names of Reporting Persons

    Steven Boyd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,736,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,736,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,736,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.23 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    KURA ONCOLOGY, INC.
    (b)Address of issuer's principal executive offices:

    4930 Directors Place, Suite 500, San Diego, CA 92121
    Item 2. 
    (a)Name of person filing:

    Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
    (b)Address or principal business office or, if none, residence:

    Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
    (c)Citizenship:

    Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    50127T109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    3,736,000
    (b)Percent of class:

    4.23%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    3,736,000

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    3,736,000 Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Armistice Capital, LLC
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd - Managing Member
    Date:05/15/2026
     
    Steven Boyd
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd
    Date:05/15/2026
    Exhibit Information

    JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: May 15, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

    Get the next $KURA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KURA

    DatePrice TargetRatingAnalyst
    4/14/2026$23.00Buy
    Lake Street
    9/4/2025Neutral
    Guggenheim
    2/6/2025Buy → Neutral
    BTIG Research
    10/24/2024$27.00Buy
    UBS
    10/14/2024$26.00 → $19.00Buy → Hold
    Stifel
    12/22/2023$26.00Buy
    Mizuho
    8/11/2023$31.00Buy
    BofA Securities
    7/27/2023$10.50Sector Perform
    Scotiabank
    More analyst ratings

    $KURA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

    – Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients – – Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients – – Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors – – New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings – – First planned platform combination, darlifarnib + da

    6/3/26 6:53:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

    – 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose – – Central MRD negativity in 75% of CRc responders with no prior venetoclax exposure; median CRc duration was 9.2 months – – Median OS not reached after median follow up of 10.7 months in patients with no prior venetoclax exposure – – Combination was well tolerated, with low rates of differentiation syndrome and QTc prolongation observed – SAN DIEGO and TOKYO, June 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA, "Kura")) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today announced the publication in Blood of updated resul

    6/2/26 8:32:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

    – Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results reinforce darlifarnib's potential as a precision combination agent across targeted therapies – – Clear clinical activity in KRASi-experienced patients and manageable safety profile – – Virtual investor event on June 3, 2026, at 12:15 p.m. PT / 3:15 p.m. ET – SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today reported compelling first-in-human data fro

    5/26/26 6:02:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    SEC Filings

    View All

    SEC Form S-8 filed by Kura Oncology Inc.

    S-8 - Kura Oncology, Inc. (0001422143) (Filer)

    6/4/26 5:25:23 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Kura Oncology, Inc. (0001422143) (Filer)

    6/4/26 4:05:17 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Kura Oncology Inc.

    DEFA14A - Kura Oncology, Inc. (0001422143) (Filer)

    5/26/26 4:38:11 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Parks Diane L.

    4 - Kura Oncology, Inc. (0001422143) (Issuer)

    6/4/26 6:30:15 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Collins Helen Louise

    4 - Kura Oncology, Inc. (0001422143) (Issuer)

    6/4/26 6:30:10 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hasnain Faheem

    4 - Kura Oncology, Inc. (0001422143) (Issuer)

    6/4/26 6:30:12 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Kura Oncology with a new price target

    Lake Street initiated coverage of Kura Oncology with a rating of Buy and set a new price target of $23.00

    4/14/26 8:04:53 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Kura Oncology

    Guggenheim initiated coverage of Kura Oncology with a rating of Neutral

    9/4/25 9:01:23 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology downgraded by BTIG Research

    BTIG Research downgraded Kura Oncology from Buy to Neutral

    2/6/25 7:53:07 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Wilson Troy Edward bought $410,145 worth of shares (50,000 units at $8.20), increasing direct ownership by 98% to 100,968 units (SEC Form 4)

    4 - Kura Oncology, Inc. (0001422143) (Issuer)

    9/9/25 4:28:40 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    Leadership Updates

    Live Leadership Updates

    View All

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

    PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS

    8/6/25 7:00:00 AM ET
    $IMNM
    $INSM
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

    – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

    10/29/24 8:00:00 AM ET
    $AMAM
    $KURA
    $RNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $KURA
    Financials

    Live finance-specific insights

    View All

    Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

    – Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients – – Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients – – Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors – – New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings – – First planned platform combination, darlifarnib + da

    6/3/26 6:53:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

    – Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results reinforce darlifarnib's potential as a precision combination agent across targeted therapies – – Clear clinical activity in KRASi-experienced patients and manageable safety profile – – Virtual investor event on June 3, 2026, at 12:15 p.m. PT / 3:15 p.m. ET – SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today reported compelling first-in-human data fro

    5/26/26 6:02:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology Reports First Quarter 2026 Financial Results

    – $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and combination adoption, reflect strong early momentum – – Broad and rapid payer access achieved, with > 93% coverage and favorable positioning across > 12 million lives – – Multiple 2026 data readouts expected to support ziftomenib as a broadly combinable backbone across AML – – $580.8 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments, expected to support advancement of ziftomenib AML program through first topline KOMET-017 Phase

    5/12/26 4:02:00 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Kura Oncology Inc.

    SC 13G - Kura Oncology, Inc. (0001422143) (Subject)

    12/5/24 6:55:37 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kura Oncology Inc.

    SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

    11/14/24 4:31:29 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kura Oncology Inc.

    SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

    11/14/24 4:32:22 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care